Development projects

1. GTU® gene therapy

Gene therapy, that is, treating or preventing a disease through gene transfer, aims at transporting desired genes into a human’s somatic cells and make those cells produce proteins that treat or prevent the disease. FIT Biotech’s goal is to develop solutions enabling gene therapy. The company has ongoing preclinical research projects to validate the efficacy of its patented GTU® technology in gene therapy. The research has produced positive results that corroborate the company’s understanding of the functioning of the technology.

During the first half of the year, FIT Biotech achieved positive preclinical results regarding the suitability of its gtGTU® technology to gene-based treatments. In these studies, FIT Biotech demonstrated the usability of the gtGTU vector for producing a therapeutic anticancer antibody in the cells. Importantly, producing this antibody through gtGTU slowed tumor growth and increased survival. These results have encouraged the Company to pursue the further development of gene-based therapies using the gtGTU vector.

2. GTU® gene vaccines

Through GTU® vaccines, the company focuses on the prevention and treatment of diseases, in particular in areas where no treatments exist at moment or medical treatment is deficient in efficacy or safety. These include a therapeutic tuberculosis vaccine, HIV immunotherapy and animal vaccines.

3. Research collaboration

Besides direct licensing agreements, the company aims at entering research agreements, through which it can move on to proper licence agreements. The company is a member of the EU´s Horizon 2020 research consortium that is developing a new kind of treatment for HIV.

4. Production

FIT Biotech manufactures test vaccines in its own production facility approved by the Finnish Medicines Agency.

Our production facility comply with regulatory requirements for DNA-base vaccines and allow flexible manufacturing of sterile and safe vaccines for clinical studies. The manufacturing equipment used is chosen to meet regulatory requirements needed for a manufacturing capacity high enough without jeopardizing sterility and safety of the vaccine.